Nano Mobile Healthcare

Nano Mobile Healthcare EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nano Mobile Healthcare (VNTH) as of Nov 5, 2026 is -1,500.00 USD.

EBITDA

-1,500.00USD

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nano Mobile Healthcare is 2022 -1,500.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nano Mobile Healthcare was 2021 0.00 USD. It decreases by % lower compared to the previous year.

The Nano Mobile Healthcare EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-6.63 M USD
Jan 1, 2015
-2.46 M USD
Jan 1, 2016
-1.69 M USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
-1,500.00 USD
The Nano Mobile Healthcare EBITDA history
YEAREBITDAYoY
-1,500.00USD—
0.00USD—
0.00USD-100.00%
-1.69 MUSD-31.39%
-2.46 MUSD-62.92%
-6.63 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nano Mobile Healthcare Stock analysis

What does Nano Mobile Healthcare do? Nano Mobile Healthcare, Inc. generates revenue through the development and sale of detection devices based on patented NASA technology. The company licenses its products from Nanobeak, which holds the original NASA patent, and focuses on disease screening and drug detection applications. Its primary customers are healthcare providers and pharmaceutical companies seeking advanced diagnostic tools. The firm's products integrate nano-electronics, bio-informatics, and wireless technology to deliver innovative screening solutions. The company's business model relies on licensing agreements with Nanobeak for the NASA-developed technology, which is then adapted for medical use. By leveraging this patented technology, Nano Mobile Healthcare targets healthcare institutions and pharmaceutical firms requiring precise diagnostic capabilities. The firm's product line centers on disease and drug screening, positioning it within the medical device sector without specifying additional market segments. Revenue streams are derived from the sale of detection devices and related services, with no mention of subscription models or additional product lines. The company's focus remains on the convergence of nano-electronics, bio-informatics, and wireless technology for medical applications, ensuring alignment with its core technological foundation. Nano Mobile Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nano Mobile Healthcare stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nano Mobile Healthcare is -1,500.00 USD in 2022.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nano Mobile Healthcare since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nano Mobile Healthcare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nano Mobile Healthcare

All Key Metrics — Nano Mobile Healthcare